Keywords

ATP-Binding Cassette Transporters; Biological Psychiatry; Blood-Brain Barrier; Blood-Retinal Barrier; Clinical Trial, Phase I; Clinical Trial, Phase II; Drug Interactions; Drug Resistance; Epilepsy, Temporal Lobe; Ethics; Organic Anion Transporters; P-Glycoprotein; Pharmacokinetics; Positron-Emission Tomography; Schizophrenia and Disorders with Psychotic Features

Research group(s)

• Section of Clinical Pharmacokinetics / Pharmacogenetics and Imaging

Research interests

An important research focus is to understand the target tissue pharmacokinetics of ABC and OATP transporter substrates. Imaging processes involving transporters such as absorption, distribution, metabolism, and excretion of a pharmaceutical compound within the human organism is our core expertise. Functional alteration of transporter processes such as up- or down regulation are often observed in various pathophysiological states and may contribute to pharmacoresistancy, drug-drug interactions or vulnerability towards diseases or drug side effects. Thus, the characterization of transporter function and modulation of transporter activity are another focus of our work.

Techniques, methods & infrastructure

Positron-emission tomography (PET) and Magnete resonance iamging (MRI) are valuable tools to investigate such processes involved in the absorption, distribution, metabolism, and excretion of a pharmaceutical compound within the human organism. Based on the microdosing concept only sub pharmacological doses of a radiolabelled compound are used to investigate drug distribution and pharmacokinetics in healthy vlunteers and patients. This study setup eases first in human trials and first application of a novel radiotracer for clinical PET imaging.

Selected publications

1. Bauer, M. et al., 2016. Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier. Clinical Pharmacology & Therapeutics, 100(2), pp.131-141. Available at: http://dx.doi.org/10.1002/cpt.362.
2. Bauer, M. et al., 2014. In vivo P-glycoprotein function before and after epilepsy surgery. Neurology, 83(15), pp.1326-1331. Available at: http://dx.doi.org/10.1212/WNL.0000000000000858.
3. Bauer, M. et al., 2016. Assessment of P-Glycoprotein Transport Activity at the Human Blood-Retina Barrier with ( R )� 11 C-Verapamil PET . Journal of Nuclear Medicine, 58(4), pp.678-681. Available at: http://dx.doi.org/10.2967/jnumed.116.182147.
4. Bauer, M. et al., 2015. Approaching Complete Inhibition of P-Glycoprotein at the Human Blood-Brain Barrier: An (R)-[11C]Verapamil PET Study. Journal of Cerebral Blood Flow & Metabolism, 35(5), pp.743-746. Available at: http://dx.doi.org/10.1038/jcbfm.2015.19.
5. Bauer, M. et al., 2011. Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Blood-Brain Barrier: A Comparison With Rat Data. Clinical Pharmacology & Therapeutics, 91(2), pp.227-233. Available at: http://dx.doi.org/10.1038/clpt.2011.217.